Company Overview

Grey Matters Health Inc. is a digital health company focused on developing and commercializing prescription digital therapeutics that use neurofeedback and software-based interventions to address mental health and neurological conditions. The company operates primarily within the digital therapeutics, mental health, and healthcare technology industries, targeting clinically validated, non-pharmacological treatments delivered through regulated medical software.

The company’s core offerings are software-based therapeutic programs designed to be prescribed by clinicians and used by patients at home, with an emphasis on conditions such as post-traumatic stress disorder (PTSD), insomnia, and anxiety-related disorders. Grey Matters Health positions itself at the intersection of neuroscience and digital medicine, emphasizing clinically validated outcomes and regulatory alignment. The company was founded in the mid-2010s and has evolved from early-stage neurotechnology research into a clinical-stage digital therapeutics developer. Public information regarding a publicly traded ticker symbol “GREY” is inconclusive based on available public sources, and the company is generally described as privately held.

Business Operations

Grey Matters Health generates value through the development, clinical validation, and commercialization of prescription digital therapeutics platforms. Its primary business activity centers on proprietary neurofeedback-based software that leverages real-time brain activity measurements to train users toward healthier neurological patterns. Revenue generation is expected to be driven by healthcare providers, payers, and institutional partnerships rather than direct-to-consumer sales, consistent with regulated digital therapeutic models.

Operations are concentrated on research and development, clinical trials, regulatory engagement, and commercialization partnerships. The company controls its core software platforms and associated clinical protocols, while relying on external healthcare systems and research institutions for validation studies. Information regarding material subsidiaries, joint ventures, or long-term strategic partnerships is limited; data inconclusive based on available public sources.

Strategic Position & Investments

Strategically, Grey Matters Health focuses on expanding the clinical indications of its digital therapeutics and achieving broader regulatory and clinical adoption. Growth initiatives center on advancing products through clinical trials, securing regulatory clearances where applicable, and integrating digital therapeutics into standard mental health treatment pathways. The company emphasizes evidence-based outcomes as a differentiator in a crowded digital mental health market.

The company has reported engagement in clinical research collaborations and pilot programs with healthcare institutions, though details on major acquisitions or equity investments are not consistently disclosed in public records. Grey Matters Health is positioned within the emerging sector of prescription digital therapeutics and neurotechnology-enabled mental health care. Specific information on portfolio companies or large-scale capital investments is inconclusive based on available public sources.

Geographic Footprint

Grey Matters Health is headquartered in the United States, with operational and research activities primarily based in North America. The company has also reported activities and collaborations involving Israel, reflecting its research roots and access to neuroscience and digital health talent in that region.

Market presence outside North America is primarily exploratory or research-oriented, with no verified evidence of large-scale commercial operations across Europe, Asia-Pacific, or other regions. International influence appears to be driven more by clinical research and technology development than by direct foreign subsidiaries or manufacturing operations.

Leadership & Governance

Grey Matters Health was founded by individuals with backgrounds in neuroscience, healthcare technology, and life sciences. Leadership emphasizes clinically rigorous innovation, regulatory credibility, and integration of digital therapeutics into mainstream healthcare systems. The company’s governance structure aligns with that of a private healthcare technology firm, with strategic oversight focused on clinical validation and long-term value creation.

Key executives identified in public disclosures include:

• Oded Kraft – Founder and Chief Executive Officer
• Roi Shternin – Chief Technology Officer
• Dr. Talma Hendler – Scientific Advisor

Information on additional executives, board composition, and formal governance committees is limited; data inconclusive based on available public sources.